Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features.

Martorell-Calatayud A, Sanmartín O, Botella-Estrada R, Balmer NN, Serra-Guillén C, Gomez-Moyano E, Traves-Zapata V, Requena C, Nagore E, Llombart-Cussac B, Guillen-Barona C.

J Am Acad Dermatol. 2011 Jun;64(6):1092-103. doi: 10.1016/j.jaad.2010.04.021. Epub 2011 Apr 13.

PMID:
21489654
2.

An intertrigo-like eruption from pegylated liposomal doxorubicin.

Korver GE, Ronald H, Petersen MJ.

J Drugs Dermatol. 2006 Oct;5(9):901-2.

PMID:
17039658
3.

[Eccrine squamous syringometaplasia from chemotherapy extravasation].

Bordel MT, Miranda A.

Actas Dermosifiliogr. 2005 Sep;96(7):462-4. Spanish.

PMID:
16476276
4.

Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells.

Valks R, Fraga J, Porras-Luque J, Figuera A, Garcia-Diéz A, Fernändez-Herrera J.

Arch Dermatol. 1997 Jul;133(7):873-8.

PMID:
9236526
5.

Vemurafenib-induced eccrine squamous syringometaplasia.

Lescoat A, Droitcourt C, Stock N, Le Gall F, Dupuy A.

Dermatology. 2013;226(4):362-4. doi: 10.1159/000351320. Epub 2013 Jul 13.

PMID:
23860306
6.

Host-vs.-altered-host eruptions in patients on liposomal doxorubicin.

Skelton H, Linstrum J, Smith K.

J Cutan Pathol. 2002 Mar;29(3):148-53.

PMID:
11972711
7.

Eccrine squamous syringometaplasia in intertriginous areas.

Valks R, Buezo GF, Daudén E, Fraga J, García-Díez A.

Br J Dermatol. 1996 May;134(5):984-6. No abstract available.

PMID:
8736357
8.

Imatinib-induced eccrine squamous syringometaplasia.

Van de Voorde K, De Raeve H, Van Regenmortel N, Lambert J.

J Am Acad Dermatol. 2006 Aug;55(2 Suppl):S58-9. No abstract available.

PMID:
16843129
9.

Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases.

Gallo E, Llamas-Velasco M, Navarro R, Fraga J, García-Diez A.

J Cutan Pathol. 2013 Mar;40(3):326-9. doi: 10.1111/cup.12041. Epub 2012 Nov 21.

PMID:
23170995
10.

[Liposomal doxorubicin and palmoplantar erythrodysesthesia].

Tomb R, Stephan F, Halaby G.

Ann Dermatol Venereol. 2003 Nov;130(11):1057-8. French. No abstract available.

PMID:
14724543
11.

Tamoxifen-induced eccrine squamous syringometaplasia.

Teoh DC, Aw DC, Jaffar H, Ling W, Yong WP, Lee YS, Choo SN, Tan KB.

J Cutan Pathol. 2012 May;39(5):554-7. doi: 10.1111/j.1600-0560.2011.01860.x. Epub 2012 Mar 6.

PMID:
22390276
12.
13.

Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin.

Garcia-Navarro X, Puig L, Fernández-Figueras MT, Alomar A.

Arch Dermatol. 2008 Oct;144(10):1402-3. doi: 10.1001/archderm.144.10.1402. No abstract available.

PMID:
18936417
14.
15.

Intertriginous eruption associated with chemotherapy in pediatric patients.

Webber KA, Kos L, Holland KE, Margolis DA, Drolet BA.

Arch Dermatol. 2007 Jan;143(1):67-71.

PMID:
17224544
16.

Eccrine squamous syringometaplasia associated with vemurafenib therapy.

Story SG, Beschloss JK, Dolan CK, Thomas BC.

J Am Acad Dermatol. 2012 Nov;67(5):e208-10. doi: 10.1016/j.jaad.2012.02.038. No abstract available.

PMID:
23062917
17.

New histopathologic findings in drug eruptions.

Fitzpatrick JE.

Dermatol Clin. 1992 Jan;10(1):19-36. Review.

PMID:
1530913
18.
19.

Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin-bound paclitaxel.

Fujii M, Takahashi I, Honma M, Ishida-Yamamoto A.

J Dermatol. 2015 Nov;42(11):1134-5. doi: 10.1111/1346-8138.13076. Epub 2015 Aug 24. No abstract available.

PMID:
26299585
20.

Neutrophilic eccrine hidradenitis: a case report and review of the literature.

Margolis DJ, Gross PR.

Cutis. 1991 Sep;48(3):198-200. Review.

PMID:
1834438

Supplemental Content

Support Center